Astria Therapeutics (ATXS) Competitors $6.81 -0.01 (-0.15%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$6.81 0.00 (0.00%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATXS vs. ARQT, AMPH, IMCR, AAPG, KNSA, DYN, GPCR, ARDX, INDV, and NRIXShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), Immunocore (IMCR), Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Ardelyx (ARDX), Indivior (INDV), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Arcutis Biotherapeutics Amphastar Pharmaceuticals Immunocore Ascentage Pharma Group International Kiniksa Pharmaceuticals Dyne Therapeutics Structure Therapeutics Ardelyx Indivior Nurix Therapeutics Astria Therapeutics (NASDAQ:ATXS) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Does the media prefer ATXS or ARQT? In the previous week, Astria Therapeutics had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 3 mentions for Astria Therapeutics and 2 mentions for Arcutis Biotherapeutics. Astria Therapeutics' average media sentiment score of 0.37 beat Arcutis Biotherapeutics' score of 0.25 indicating that Astria Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astria Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in ATXS or ARQT? 99.0% of Astria Therapeutics shares are owned by institutional investors. 2.9% of Astria Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, ATXS or ARQT? Astria Therapeutics has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAstria TherapeuticsN/AN/A-$72.89M-$2.09-3.26Arcutis Biotherapeutics$59.61M25.56-$262.14M-$1.79-7.27 Which has more risk and volatility, ATXS or ARQT? Astria Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Does the MarketBeat Community prefer ATXS or ARQT? Astria Therapeutics received 506 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. Likewise, 73.04% of users gave Astria Therapeutics an outperform vote while only 65.63% of users gave Arcutis Biotherapeutics an outperform vote. CompanyUnderperformOutperformAstria TherapeuticsOutperform Votes56973.04% Underperform Votes21026.96% Arcutis BiotherapeuticsOutperform Votes6365.63% Underperform Votes3334.38% Is ATXS or ARQT more profitable? Astria Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Astria Therapeutics' return on equity of -43.58% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Astria TherapeuticsN/A -43.58% -29.36% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Do analysts recommend ATXS or ARQT? Astria Therapeutics presently has a consensus target price of $25.67, suggesting a potential upside of 276.90%. Arcutis Biotherapeutics has a consensus target price of $16.60, suggesting a potential upside of 27.50%. Given Astria Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Astria Therapeutics is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryAstria Therapeutics beats Arcutis Biotherapeutics on 13 of the 17 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$384.88M$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.9318.2614.95Price / SalesN/A281.18434.4770.76Price / CashN/A65.9238.4235.17Price / Book2.056.717.644.65Net Income-$72.89M$138.11M$3.18B$245.69M7 Day Performance-3.54%-2.54%-1.95%-2.68%1 Month Performance-9.20%-2.00%-0.23%-2.16%1 Year Performance-46.04%-5.04%16.69%12.90% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics1.9924 of 5 stars$6.81-0.1%$25.67+276.9%-47.5%$384.88MN/A0.0030ARQTArcutis Biotherapeutics2.4746 of 5 stars$12.78+3.8%$16.60+29.9%+40.5%$1.50B$59.61M-7.14150Upcoming EarningsAMPHAmphastar Pharmaceuticals4.434 of 5 stars$31.02-2.3%$50.33+62.3%-39.0%$1.49B$644.40M10.341,761IMCRImmunocore1.433 of 5 stars$29.60-0.5%$65.64+121.7%-57.4%$1.48B$249.43M-31.16320AAPGAscentage Pharma Group InternationalN/A$18.24+5.7%N/AN/A$1.44BN/A0.00600News CoverageGap UpKNSAKiniksa Pharmaceuticals3.1847 of 5 stars$19.74+0.5%$36.60+85.4%+0.3%$1.43B$270.26M-140.99220Upcoming EarningsDYNDyne Therapeutics3.0716 of 5 stars$13.91-1.0%$49.91+258.8%-37.9%$1.42BN/A-3.91100GPCRStructure Therapeutics2.5058 of 5 stars$24.39+0.1%$81.29+233.3%-42.2%$1.40BN/A-32.96136ARDXArdelyx4.3501 of 5 stars$5.79+2.3%$9.42+62.6%-40.5%$1.37B$124.46M-19.3090Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageINDVIndivior3.6113 of 5 stars$9.83-2.5%$16.00+62.8%-51.6%$1.36B$1.18B-245.691,164Earnings ReportAnalyst RevisionNews CoverageNRIXNurix Therapeutics1.557 of 5 stars$17.59+0.1%$31.81+80.9%+68.0%$1.33B$54.55M-6.09300 Related Companies and Tools Related Companies Arcutis Biotherapeutics Competitors Amphastar Pharmaceuticals Competitors Immunocore Competitors Ascentage Pharma Group International Competitors Kiniksa Pharmaceuticals Competitors Dyne Therapeutics Competitors Structure Therapeutics Competitors Ardelyx Competitors Indivior Competitors Nurix Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATXS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXS Stock Alerts